MAPT and Alzheimer disease: Based on these last approaches, and in parallel to this study, Ionis, in partnership with Biogen Inc., Cambridge, and Massachusetts, has developed the first-ever trial of a tau antisense oligonucleotide (ASO) in mild Alzheimer’s disease.